{"transactions":[{"id":2401181,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-11T18:09:14.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":58600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares vest monthly following February 9, 2022."}],"balance_after":58600,"derivative":{"exercise_price":37.68,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":58600},"source":{"system":"sec-edgar","filing":"0001209191-22-008981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919122008981/doc4.xml","form_type":"4"}},{"id":2401180,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2022-02-11T18:09:14.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":16283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan."}],"balance_after":27979,"source":{"system":"sec-edgar","filing":"0001209191-22-008981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919122008981/doc4.xml","form_type":"4"}},{"id":2401179,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2022-02-11T18:09:14.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":669,"price":36.3,"value":24284.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021."}],"balance_after":11696,"source":{"system":"sec-edgar","filing":"0001209191-22-008981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919122008981/doc4.xml","form_type":"4"}},{"id":2584853,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-08-31T17:26:57.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":144609,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-054117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121054117/doc4.xml","form_type":"4"}},{"id":2584852,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-08-31T17:26:57.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":10000,"price":80,"value":800000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":12365,"source":{"system":"sec-edgar","filing":"0001209191-21-054117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121054117/doc4.xml","form_type":"4"}},{"id":2584851,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-08-31T17:26:57.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":10000,"price":17,"value":170000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":22365,"source":{"system":"sec-edgar","filing":"0001209191-21-054117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121054117/doc4.xml","form_type":"4"}},{"id":2665805,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T17:16:10.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":154609,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-040984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121040984/doc4.xml","form_type":"4"}},{"id":2665804,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-06-16T17:16:10.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":6634,"price":77.82,"value":516257.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $77.82, and the range of prices were between $77.59 and $78.21.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":12365,"source":{"system":"sec-edgar","filing":"0001209191-21-040984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121040984/doc4.xml","form_type":"4"}},{"id":2665803,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-06-16T17:16:10.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":2700,"price":77.37,"value":208899.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $77.37, and the range of prices were between $76.575 and $77.55.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":18999,"source":{"system":"sec-edgar","filing":"0001209191-21-040984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121040984/doc4.xml","form_type":"4"}},{"id":2665802,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-06-16T17:16:10.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":5666,"price":75.94,"value":430276.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $75.94, and the range of prices were between $75.49 and $76.35.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":21699,"source":{"system":"sec-edgar","filing":"0001209191-21-040984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121040984/doc4.xml","form_type":"4"}},{"id":2665801,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-06-16T17:16:10.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":15000,"price":17,"value":255000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":27365,"source":{"system":"sec-edgar","filing":"0001209191-21-040984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121040984/doc4.xml","form_type":"4"}},{"id":2722636,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-05-07T16:37:06.000Z","date":"2021-05-06","kind":"exercise","acquired":false,"shares":5882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":169609,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":5882},"source":{"system":"sec-edgar","filing":"0001209191-21-030925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121030925/doc4.xml","form_type":"4"}},{"id":2722635,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-05-07T16:37:06.000Z","date":"2021-05-06","kind":"exercise","acquired":true,"shares":5882,"price":17,"value":99994.0,"ownership":{"direct":true},"balance_after":12365,"source":{"system":"sec-edgar","filing":"0001209191-21-030925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121030925/doc4.xml","form_type":"4"}},{"id":2799199,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":175491,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799198,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":700,"price":111.69,"value":78183.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $111.69, and the range of prices were between $111.52 and $111.89.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":6483,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799197,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":4571,"price":110.77,"value":506329.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $110.77, and the range of prices were between $110.48 and $111.47.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7183,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799196,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":9419,"price":109.89,"value":1035053.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $109.89, and the range of prices were between $109.47 and $110.47.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":11754,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799195,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":4810,"price":109.09,"value":524722.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $109.09, and the range of prices were between $108.46 and $109.41.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":21173,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799194,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":500,"price":103.3,"value":51650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":25983,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2799193,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-03-09T19:26:01.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":20000,"price":17,"value":340000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":26483,"source":{"system":"sec-edgar","filing":"0001209191-21-019268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121019268/doc4.xml","form_type":"4"}},{"id":2868712,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right  to buy)","published_at":"2021-02-10T18:01:24.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":29175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares vest monthly following February 8, 2021."}],"balance_after":29175,"derivative":{"exercise_price":140.01,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":29175},"source":{"system":"sec-edgar","filing":"0001209191-21-009375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121009375/doc4.xml","form_type":"4"}},{"id":2868711,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-10T18:01:24.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":6483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan."}],"balance_after":6483,"source":{"system":"sec-edgar","filing":"0001209191-21-009375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121009375/doc4.xml","form_type":"4"}},{"id":2884937,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":9016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":195491,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":9016},"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884936,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":15984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":204507,"derivative":{"exercise_price":17,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":15984},"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884935,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":604,"price":131.89,"value":79661.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The weighted average sale price for the transaction reported was $131.89, and the range of prices were between $131.52 and $132.25.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884934,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":3752,"price":130.64,"value":490161.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The weighted average sale price for the transaction reported was $130.64, and the range of prices were between $130.23 and $131.23.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":604,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884933,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":2860,"price":129.75,"value":371085.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The weighted average sale price for the transaction reported was $129.75, and the range of prices were between $129.22 and $130.21.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":4356,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884932,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":500,"price":128.74,"value":64370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The weighted average sale price for the transaction reported was $128.74, and the range of prices were between $128.12 and $129.07.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7216,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884931,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":900,"price":127.83,"value":115047.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $127.83, and the range of prices were between $127.72 and $127.99.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7716,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884930,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":400,"price":126.66,"value":50664.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $126.66, and the range of prices were between $126.30 and $127.05.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":8616,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884929,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":9016,"price":17,"value":153272.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":9016,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884928,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":500,"price":125.38,"value":62690.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $125.38, and the range of prices were between $125.05 and $126.55.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884927,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":3313,"price":124.41,"value":412170.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $124.41, and the range of prices were between $124.02 and $124.89.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884926,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":10541,"price":123.49,"value":1301708.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $123.49, and the range of prices were between $123.01 and $124.00.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":3813,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884925,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":1630,"price":122.58,"value":199805.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $122.58, and the range of prices were between $121.95 and $122.90.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":14354,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":2884924,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Common Stock","published_at":"2021-02-02T21:50:16.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":15984,"price":17,"value":271728.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":15984,"source":{"system":"sec-edgar","filing":"0001209191-21-007041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919121007041/doc4.xml","form_type":"4"}},{"id":3315085,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Secty."}}],"security":"Stock Option (right to buy)","published_at":"2020-01-08T16:20:22.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares will vest each month following January 6, 2020, so that all of the shares are vested four (4) years after January 6, 2020."}],"balance_after":56000,"derivative":{"exercise_price":63.33,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001209191-20-002513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341011/000120919120002513/doc4.xml","form_type":"4"}},{"id":3688005,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Option to purchase common stock","published_at":"2019-01-24T21:11:53.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 equal monthly installments commencing on the grant date."}],"balance_after":100000,"derivative":{"exercise_price":15.47,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-005134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919119005134/doc4.xml","form_type":"4"}},{"id":4088083,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Option to purchase common stock","published_at":"2018-01-26T21:28:40.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 equal monthly installments commencing on the grant date."}],"balance_after":70000,"derivative":{"exercise_price":20,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-005608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919118005608/doc4.xml","form_type":"4"}},{"id":4481859,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":130569,"kind":"person","name":"North Annette","position":1,"cik":"0001341011","reported_name":"North Annette","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Option to purchase common stock","published_at":"2017-01-25T22:32:25.000Z","date":"2017-01-23","kind":"grant","acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 equal monthly installments commencing on the grant date."}],"balance_after":72000,"derivative":{"exercise_price":6.15,"expiration_date":"2027-01-22","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001209191-17-005568","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919117005568/doc4.xml","form_type":"4"}}]}